• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Trovagene inks agreement with Lurie Comprehensive Cancer Center, NMDTI

Trovagene inks agreement with Lurie Comprehensive Cancer Center, NMDTI

June 30, 2014
CenterWatch Staff

Trovagene has partnered with the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and the Northwestern Medicine Developmental Therapeutics Institute (NMDTI) to conduct a translational research program designed to assess the utility of Trovagene's urine-based cell-free oncogene mutation monitoring technology in clinical practice.

The Lurie Cancer Center and NMDTI will work with Trovagene on clinical protocols that incorporate oncogene mutation monitoring during the course of cancer treatment and will assess the impact on overall disease management and patient outcomes.

"The Lurie Cancer Center is focused on advancing personalized medicine through collaborations with developers of state-of-the-art genomic technologies, such as Trovagene, to facilitate clinical decision making and improve patient care," said Leonidas C. Platanias, M.D., Ph.D., interim director of the Lurie Cancer Center.

"We are excited about the increasing opportunities to tailor cancer treatment to the specific genetic abnormalities that drive disease, and…we are dedicated to the rapid integration of technologies that will make patient-specific therapy an affordable reality," said Francis J. Giles, M.D., associate director for Translational Medicine and Developmental Therapeutics at the Lurie Cancer Center and director of the NMDTI.

Trovagene is engaged in clinical collaborations with academic institutions and integrated healthcare networks to demonstrate the clinical utility of its precision cancer monitoring platform for the detection of oncogene mutations, and the assessment of tumor dynamics and treatment response over time. The company is focused on expanding the clinical evidence to support broad market adoption of its molecular diagnostic platform and to generate health economic data necessary to establish favorable reimbursement. Trovagene's precision cancer monitoring platform can detect cell-free DNA mutations in urine and provide physicians with a whole-body molecular view of the patient in order to determine mutational status, guide treatment selection and to monitor disease progression over time.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing